DR info

臨床試験数 : 28 / 薬物数 : 22 - (DrugBank : 5) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 59

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

ACZ885
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharmaceuticals
      -   -   EUCTR2015-003527-57-Outside-EU/EEA   Turkey;
      -   -   EUCTR2015-003522-13-Outside-EU/EEA   Israel;
ACZ885, 150mg/1.0ml
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
Canakinumab
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01148797   Israel;
      2010   Phase 2   NCT01088880   Turkey;
Colchicine
   Gulhane Military Medical Academy
      2011   Phase 4   NCT02602028   Turkey;
   Rambam Health Care Campus
      2014   Phase 2   NCT02175589   Israel;
   Sheba Medical Center
      2017   -   NCT03210610   Israel;
Colchicine sprinkle capsules
   Mutual Pharmaceutical Company, Inc.
      2010   Phase 1   NCT01075906   Armenia;Israel;Turkey;United States;
IL-1 Trap
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2004   Phase 2   NCT00094900   United States;
INN-Tocilizumab
   University Hospital Tuebingen
      2017   Phase 2   EUCTR2016-004505-13-DE   Germany;
Ilaris
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States;
   Novartis Pharmaceuticals
      -   -   EUCTR2015-003527-57-Outside-EU/EEA   Turkey;
      -   -   EUCTR2015-003522-13-Outside-EU/EEA   Israel;
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan;
Kineret
   Sheba Medical Center
      2012   Phase 3   NCT01705756   Israel;
One additional blood sample during a planned blood test
   Hospices Civils de Lyon
      2021   -   NCT04478409   France;
Probiotic
   Rambam Health Care Campus
      2013   -   NCT02021084   -
RPH-104
   R-Pharm International, LLC
      2021   Phase 2   NCT05190991   Armenia;Georgia;Russian Federation;
Rilonacept
   The Cleveland Clinic
      2008   Phase 2   NCT00582907   United States;
RoActemra® 20mg/ml Konzentrat
   University Hospital Tuebingen
      2017   Phase 2   EUCTR2016-004505-13-DE   Germany;
Tocilizumab
   Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
      2018   -   JPRN-UMIN000032557   Japan;
      2018   -   JPRN-UMIN000028010   Japan;
Tocilizumab Infusion RoAcemtra (EU)
   University Hospital Tuebingen
      2018   Phase 2   NCT03446209   Germany;
Wheat
   University of Palermo
      2018   -   NCT03563300   Italy;
physiological saline
   University Hospital Tuebingen
      2018   Phase 2   NCT03446209   Germany;